Epirubicin and Thalidomide in Treating Patients With Liver Cancer
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy such as epirubicin use different ways to stop tumor
cells from dividing so they stop growing or die. Thalidomide may stop the growth of
hepatocellular (liver) cancer by stopping blood flow to the tumor. Combining epirubicin with
thalidomide may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining epirubicin with thalidomide
in treating patients who have unresectable or metastatic liver cancer.